The Hong Kong Stock Exchange and the Shanghai Stock Exchange have successively introduced the 18A listing rules and the fifth set of listing rules for the Sci-Tech Innovation Board, allowing unprofitable biotech companies to apply for listing. As of September 25, 2023, over 80 biotech companies have seized the opportunity to successfully list, sparking a wave of interaction between the industry and the capital market.
On September 27, at the 2023 Second New Investment Expo and the 17th Frost & Sullivan Global Growth, Sci-Tech Innovation and Leadership Summit (NIE), Life Sciences New Investment Summit Forum, Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') jointly with TradeGo and LeadLeo officially released the '2023 18A & Sci-Tech Innovation Board Biotech Industry Development Blue Book' (hereinafter referred to as the 'Blue Book'). The report aims to sort out the ecosystem and industrial development pattern of the Hong Kong 18A and Sci-Tech Innovation board biotech industries for the Chinese industry, and further provide cutting-edge insights for market participants.
